Summary
Reasons to purchase (USPs and key questions answered)
Partneringdesk Altana AG Deals briefing provides a comprehensive summary of the deals and alliances announced by the company and its subsidiaries between January 2000 and July 2005. This report helps in:
- identifying active partners
- tracking competitor activity
- benchmarking deals
- comparing the finances of different deal types.
Partneringdesk Altana AG Deals briefing brings all relevant partnering deals into one place, providing a reference to deal making by Altana AG.
Report scope
The report contains:
- a brief company profile including subsidiary names
- financial information where disclosed
- a deals overview
- specialized indexes including deals by partner company, subsidiary company, therapy focus and development stage
- a detailed listing of the company's deals and alliances.
Forecasts, projections, market estimates
This report provides: a financial summary table detailing the yearly total revenues, pharma revenues, R&D spend and profit of the company; and a series of tables detailing the number of deals made by deal type, by therapy focus, by development stage and by industry sector.
Description
Partneringdesk Altana AG Deals briefing provides an in-depth view of the 26 deals made by Altana AG and its subsidiaries with 31 partnering companies between 2000 and 2005, in a clear and accessible PDF format.
Chapter 1: Company profile
An overview of the company, including contact details, a summary of business and partnering interests, and a review of management
Chapter 2: Financial data and deals overview
A summary of the company's financial status and overview of the numbers of deals by deal type, therapy focus, deal stage and industry sector.
Chapter 3: Summary of deals
A comprehensive overview listing deals by partner company, therapy focus and development stage, with a full index of all the deals announced.
Chapter 4: List of deals
A detailed listing of all the company's deals and alliances announced between January 2000 and July 2005.
Pharmaceutical Executive Top 50, May 2005
Every deal is fully categorized, includes a detailed description, and includes financials such as headline value, upfront payments and royalty rates, where disclosed.
Who should buy the report
This report is essential reading for board and executive management, and individuals in:
- business development
- licensing/partnering
- deal making
- business strategy
- marketing and promotion
- distribution and manufacturing (including contract services).
Methodology
This report is derived from data obtained from Pharmalicensing's Partneringdesk deals and alliances database. The database is updated daily using industry sources.
Companies analyzed/mentioned
The report includes deals made by Altana AG between January 2000 and July 2005 and the following subsidiaries (where available):
- Altana Pharma AG
- Byk & DiaSorin Diagnostics GmbH (until
- 2002-11-01)
- Byk Diagnostica Srl (until 2002-11-01)
- Byk Gulden
- Byk Sangtec Diagnostica GmbH (until 2002-11-01)
- Sangtec Medical AB (until 2002-11-01)
- Sangtec Molecular Diagnostics
Report summary
Partneringdesk Altana AG Deals briefing provides an in-depth view of the 26 deals made by Altana AG and its subsidiaries with 31 partnering companies between 2000 and 2005, in a clear and accessible PDF format.
|
